Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.

Szczegóły
Abstrakt

Tytuł:: Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.
Autorzy:: Lindenmayer JP; From the Department of Psychiatry, NYU School of Medicine, Manhattan Psychiatric Center.
Glick ID; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine.
Talreja H
Underriner M; Department of Psychiatry, NYU School of Medicine, New York City, NY.
Źródło:: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2020 Jul/Aug; Vol. 40 (4), pp. 346-349.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Baltimore Md : Williams And Wilkins
Original Publication: Baltimore, Md. : Williams & Wilkins, [c1981-
MeSH Terms:: Delayed-Action Preparations*
Health Services Accessibility*
Injections, Intramuscular*
Antipsychotic Agents/*therapeutic use
Schizophrenia/*drug therapy
Antipsychotic Agents/administration & dosage ; Humans
References:: Glick ID, Davis JM, Zamora D, et al. Should antipsychotic medications for schizophrenia be given for a lifetime? A naturalistic long-term follow-up study. J Clin Psychopharmacol. 2017;37:125–130.
Leucht S, Tardy M, Komosa K, et al. Antipsychotic drug versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–2071.
Ascher-Svanum H, Peng X, Faries D, et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry. 2009;9:46–46.
Taipale H, Mehtälä J, Tanskanen A, et al. Comparative effectiveness ofAntipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44:1381–1387.
Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-actinginjectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58:23S–29S.
Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30:689–701.
Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67:1948–1953.
Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175:58–62.
Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28:210–213. Erratum in: J Clin Psychopharmacol. 2008; 28:624.
Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46:1049–1054.
Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22:275–282.
Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-actinginjectable antipsychotics: part I-patient perspectives. Can J Psychiatry. 2013;58:14S–22S.
Patel MX, Haddad PM, Chaudhry IB, et al. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24:1473–1482.
Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27:637–652.
Patel MX, de Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol. 2010;24:1483–1489.
Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol. 2014;4:179–185.
Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand. 1997;95:464–468.
Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300–307.
Velligan DI, Medellin E, Draper M, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J. 2011;47:654–659.
West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56:283–291.
Sajatovic M, Ross R, Legacy SN, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018;14:1463–1474.
Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40:355–366.
Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77:1–24.
Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192–213.
Substance Nomenclature:: 0 (Antipsychotic Agents)
0 (Delayed-Action Preparations)
Entry Date(s):: Date Created: 20200709 Date Completed: 20210121 Latest Revision: 20220420
Update Code:: 20240105
DOI:: 10.1097/JCP.0000000000001225
PMID:: 32639287
: Czasopismo naukowe

Purpose/background: One of the major challenges in the treatment of schizophrenia is nonadherence, defined as the failure to take medications as prescribed. Nonadherence is a strong predictor of symptom relapse, hospital readmission, and poorer long-term outcome. Although long-acting injectable antipsychotics (LAIs) have been found to be superior to their oral analogs at reducing relapse in large-scale meta-analyses, their prevalence seldom exceeds 30% even in populations with a history of nonadherence. We review multiple barriers to the use of LAI utilization and suggest strategies to address them.
Methods/procedures: We searched for the following terms: long-acting injectable/depot antipsychotics, schizophrenia, barriers, and attitude/perception in both the PubMed search index and Google scholar from 1995 to 2018. A total of 329 studies were selected, of which data from 13 were reviewed for this article. Only peer-reviewed studies, randomized controlled trials, systematic reviews, and meta-analyses that describe barriers to using LAIs were included.
Findings/results: Several barriers to using LAIs were identified. These are organized into 3 overarching categories: those related to the clinician; those related to the patient; and systems barriers. Clinician factors include the perception of LAIs as coercive, fears of not being able to control the dose, as well as current practice patterns and guidelines. Patient factors include perception of the injection as painful or intrusive, general lack of knowledge, and a sense of coerciveness. For each identified barrier, we propose potential solutions.
Implications/conclusions: We identified multiple barriers to using LAIs in patients with schizophrenia. Specific strategies are suggested for overcoming each of these barriers.

Informacja